臨床試驗

StrataCTX® as a Steroid Sparing Device

NCT：NCT04087629 · RECRUITING

NCT IDNCT04087629

狀態RECRUITING

開始日期2021-07-07

SponsorColumbia University (OTHER)

First posted2019-09-12

Last updated2026-09-11

簡要摘要

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。